FCGR2A and nonpapillary renal cell carcinoma: These insights underscore the urgency of redefining therapeutic paradigms in ccRCC to account for metabolic comorbidities, with FCGR2A emerging as both a biomarker and a tractable target for combinatorial immunotherapy (84).